secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001193125-26-193945
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Pharma Q1 net rev $58.3M (+104% YoY); maintains FY 2026 op profitability guidance
--------------------------------------------------------------------------------

- Q1 net revenues $58.3M vs $28.5M YoY; net loss $30.4M vs $94.3M YoY.
- Non-GAAP operating expenses $56.2M, down ~43% YoY; cash and equivalents $180.9M.
- ~1.35M total VOQUEZNA prescriptions filled to date; Q1 covered prescriptions up 91% YoY.
- FY 2026 guidance: net rev $320-345M, non-GAAP op ex $235-255M; op profitability expected Q3 2026.
- EoE phase 2 trial (pHalcon-EoE-201) topline results expected late Q4 2026/early Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/0001193125-26-193945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/d140332d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-193945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer